World Journal of Clinical Cases - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

JOURNAL HOME

Number of total visits: 4212971

Number of visits today: 1087

Number of downloads: 3847831

MEMBERSHIP

BPG JOURNALS

Cited by in F6Publishing

For:	Shin HJ, Kho BG, Kim MS, Park HY, Kim TO, Kim YI, Lim SC, Park CK, Kim YC, Choi YD, Oh IJ. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. Medicine (Baltimore) 2019;98:e14699. [PMID: 30817606 DOI: 10.1097/MD.0000000000014699] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]

For:

Shin HJ, Kho BG, Kim MS, Park HY, Kim TO, Kim YI, Lim SC, Park CK, Kim YC, Choi YD, Oh IJ. Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series. Medicine (Baltimore) 2019;98:e14699. [PMID: 30817606 DOI: 10.1097/MD.0000000000014699] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]

Number	Citing Articles
1	Zhong WX, Wei XF. Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study. World J Clin Cases 2022; 10(33): 12164-12174 [DOI: 10.12998/wjcc.v10.i33.12164] [Reference Citation Analysis]
2	Noronha V, Chougule A, Chandrani P, Kaushal RK, Patil VM, Menon N, Kapoor A, Chopade S, Singh A, Shetty O, Dutt A, Banavali S, Prabhash K. Lung cancer with dual EGFR and ALK driver alterations at baseline: a retrospective observational cohort study. Acta Oncol 2022;:1-5. [PMID: 35972844 DOI: 10.1080/0284186X.2022.2109426] [Reference Citation Analysis]
3	Behel V, Noronha V, Patil V, Menon N, Chandrani P, Kumar R, Rastogi S, Mahajan A, Chougule A, Dutt A, Prabhash K. Molecular tumor board–guided treatment of non-small-cell lung cancer with dual driver (ALK and EGFR) alterations. Cancer Res Stat Treat 2022;5:312. [DOI: 10.4103/crst.crst_114_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4	Yin Q, Guo T, Zhou Y, Sun L, Meng M, Ma L, Wang X. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion. Thoracic Cancer. [DOI: 10.1111/1759-7714.14291] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5	Lu Z, Wang X, Luo Y, Wei J, Zeng Z, Xiong Q, Cai J, Liu A. EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report. Onco Targets Ther 2021;14:2823-8. [PMID: 33935502 DOI: 10.2147/OTT.S294635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]